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The ultimate goal of our research is the regulation of cellular functions by designed peptides and proteins. Current 
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In Vivo Tumor Accumulation of Arginine-rich 
Cell-penetrating Peptides and Anticancer 
Drug Delivery
In this study, we investigated the biodistribution of 
arginine-rich cell-penetrating peptides (CPPs) in tumor-
xenografted nude mice using in vivo imaging after the 
intravenous injection of the fluorescently labeled CPPs. 
There have been several reports about the in vivo distribu-
tion of arginine-rich CPPs and their conjugates that often 
suggest their tendencies to accumulate in some organs. 
However, few reports have been published that studied the 
biodistribution of CPPs in tumor-xenografted mice.
Using typical arginine-rich CPPs, this study determined 
that there is a considerable difference among these 
peptides regarding their tendencies of tumor accumulation. 
Tat, Penetratin and octaarginine (R8) showed almost a 
similar degree of accumulation in the kidney, liver and 
lung, however, R8 showed a higher accumulation in the 
tumor xenografts. A comparison of the tendency for tumor 
accumulation of the oligoarginines composed of different 
numbers of argninines (R2, R8, R12, and R16) revealed 
that the R8 peptide showed the highest accumulation in a 
tumor. A further increase in tumor accumulation was 
observed by the D-substitution of the amino acids of R8 
peptide (r8).
To exemplify the applicability of the r8 peptide for 
cancer therapy, the conjugate of doxorubicin with r8 was 
prepared. The r8-doxorubcin conjugate (4 mg doxorubcin/
kg) effectively suppressed the tumor proliferation without 
a decrease in the mouse weight after intravenous injection 
of the conjugate. A higher dose of doxorubicin (6 mg/kg) 
was necessary to obtain the same extent of tumor growth 
suppression effect without conjugation to r8, but this was 
accompanied by a significant weight loss of the mice. 
These results suggested the potential of r8 as a prototype 
of tumor-targeting vectors.
Control of Circadian Phase by an Artificial 
Zinc Finger Transcription Regulator
Circadian time originates from clock genes interlocked 
in transcription/translation feedback loops. In spite of the 
increase in fundamental knowledge of the circadian 
molecular machinery in the past decade, practical applica-
tions have been so far lacking, and no attempts have been 
performed in the adjustment of circadian time via a direct 
action on the core-clock components. Recently, C2H2-
type zinc-finger-based artificial DNA binding proteins 
have seen tremendous development, and can be used to 
specifically and efficiently manipulate the expression of a 
target gene.
Here we designed a C2H2-type zinc-finger-based arti-
ficial DNA binding protein, ZF(dGRE), that can specifi-
cally recognize the glucocorticoid responsive element 
(GRE) in the regulatory region of the Period1 gene. A 
chromatin immunoprecipitation (ChIP) assay indicated 
that the DNA binding activity and sequence specificity of 
ZF(dGRE) are functionally preserved even when its DNA 
target site is chromosomally structured within the cells. To 
control the time-specificity of our zinc-finger construct, 
we added the ligand-controllable destabilizing domain 
and a transcriptional activation domain to ZF(dGRE). The 
ligand-inducible accumulation of this artificial transcrip-
tion factor in the nucleus led to the consolidation of circa-
dian rhythms and to circadian phase resetting (Figure 2). 
To our knowledge, this is the first report of an artificially 
designed protein that can externally control cellular clock 
at the genomic level. In addition, our results suggest that 
mPeriod1 is a state variable in the generation of circadian 
rhythms. This artificial transcription factor, which directly 
controls the clock machinery, potentially opens the way 
towards novel and effective chronotherapy by tuning 
circadian time.
Figure 1. Tumor accumulation of fluorescently labeled r8 peptide 
intravenously administrated into tumor-bearing mouse.
Figure 2. Induction of circadian phase shifts by an artificial transcription 
factor specifically targeting a glucocorticoid response element of the 
mPeriod1 gene.
